Introduction {#s1}
============

Acute minor ischemic stroke and high risk transient ischemic attack (TIA) are very common. The combination of clopidogrel and aspirin is recommended for secondary prevention of patients with acute minor stroke or TIA ([@B1]--[@B5]). However, the incidence of clopidogrel resistance ranges from 5 to 30% ([@B6]). Among many factors related to clopidogrel resistance, the *CYP2C19* loss-of-function (LOF) alleles, particularly, ^\*^2 and ^\*^3, are associated with poor clopidogrel metabolism ([@B7], [@B8]).

Ticagrelor, a reversible P2Y12 receptor antagonist, inhibits platelet reactivity irrespective of *CYP2C19* genotypes ([@B9], [@B10]). Previous studies demonstrated that ticagrelor is more reliable than clopidogrel in inhibiting platelet reactivity and reducing the recurrence of ischemic vascular events in patients with acute coronary syndrome ([@B11]--[@B13]). In recent years, more and more clinical trials have focused on the application of ticagrelor among patients with cerebrovascular events ([@B14]--[@B16]). However, whether ticagrelor is superior to clopidogrel in reducing stroke recurrence in patients with acute minor stroke or high-risk TIA remains unclear.

Platelet function tests can assess the response variability to antiplatelet therapies. High on-treatment platelet reactivity (HOPR) is thought to be strongly associated with ischemic events, and the proportion of HOPR could reflect the efficacy of antiplatelet therapy ([@B17], [@B18]). Platelet Reactivity in Acute Non-disabling Cerebrovascular Events (PRINCE) trial showed that ticagrelor had a lower proportion of HOPR assessed by VerifyNow P2Y12 assay than clopidogrel in patients with minor stroke and TIA ([@B16]). Aggrestar (PL) platelet function analyzer is a novel analyzer via sequential platelet counting method and it\'s cheap, quick and easy to monitor platelet function ([@B19]). In this pre-specified subgroup analysis of PRINCE trial, we aimed to investigate the comparative effects of ticagrelor plus aspirin vs. clopidogrel plus aspirin on platelet reactivity, which was assessed by the PL platelet function analyzer, and whether *CYP2C19* genotypes were involved in the process.

Materials and Methods {#s2}
=====================

Study Population
----------------

A pre-specified subgroup analysis of PRINCE trial was conducted, which was a randomized, prospective, multicenter, open-label, active-controlled, blind-endpoint trial. The rationale and design of PRINCE trial have been described previously ([@B20]). Briefly, the trial randomized patients with acute minor ischemic stroke (National Institutes of Health Stroke Scale score ≤3), or moderate to high risk TIA (ABCD^2^ stroke risk score of ≥ 4 or ≥ 50% stenosis of cervical or intracranial vessels that could account for the presentation) to receive ticagrelor plus aspirin or clopidogrel plus aspirin within 24 h of symptoms onset. Participants received ticagrelor (180 mg on day 1, followed by 90 mg twice daily on days 2--90) or clopidogrel (300 mg on day 1, followed by 75 mg daily on days 2--90) with an aspirin background using (300 mg on day 1, followed by 100 mg daily on days 2--21). Patient enrolment began in China in August 2015, and patient follow-up was completed by June 2017. Of the 26 centers included in PRINCE trial, participants in 17 centers voluntarily participated in the subgroup in which the platelet reactivity was measured by the PL platelet analyzer. The trial was registered with [ClinicalTrials.gov](https://ClinicalTrials.gov) (NCT02506140).

Measurement of Platelet Reactivity
----------------------------------

Platelet reactivity was assessed using the PL platelet function analyzer (Sinnowa Medical Science & Technology Co., Nanjing, China) at baseline, 7 + 2 days and 90 ± 7 days after randomization. Arachidonic acid (AA) (2 mg/mL) or adenosine diphosphate (ADP) (50 μmol/L) were used as inductive agents, and 40 μL of each were added to the samples, which were then mixed to initiate platelet aggregation. The analyzer counted the platelets several times until the lowest level was detected. The maximum aggregation ratio (MAR) value was calculated following exposure to each inductive agent. HOPR on ticagrelor or clopidogrel was defined as MAR~ADP~ ≥ 35%, and HOPR on aspirin was defined as MAR~AA~ ≥ 35% ([@B21]). Considering that aspirin was only given for the first 21 days, we didn\'t evaluate MAR~AA~ at 90 ± 7 days. In addition, VerifyNow testing was conducted for these patients and P2Y12 reaction unit was measured at 90 ± 7 days ([@B20]).

At 7 + 2 days and 90 ± 7 days, blood for platelet function evaluation was sampled between 2 and 4 h after the morning maintenance dose of antiplatelet drugs. Platelet function needed to be assessed within 2 h after blood was sampled. Platelet function testing was conducted according to a standardized procedure manual in each study center by qualified personnel who were blinded to treatment allocation. Both the investigators and patients were aware of the study drug assignment, but were blinded to platelet reactivity data until the end of the trial. To ensure the validity and reproducibility of these methods, we held two separate training courses for all the testing personnel from each center.

Clinical Outcomes
-----------------

Efficacy outcomes included any stroke (ischemic/hemorrhagic) and composite vascular events (ischemic/hemorrhagic stroke, TIA, myocardial infarction, or vascular death) at 90 days. Safety outcomes included bleeding events at 90 days which were defined according to PLATO criteria ([@B22]).

*CYP2C19* Genotyping
--------------------

Blood samples were collected and shipped via cold-chain transportation from each center to Beijing Tiantan Hospital and stored at −80°C. Three *CYP2C19* single-nucleotide polymorphisms (SNPs) were assessed: *CYP2C19*^\*^*2* (681G \> A, dbSNP rs4244285), *CYP2C19*^\*^*3* (636G \> A, dbSNP rs4986893), and *CYP2C19*^\*^*17* (−806C \> T, dbSNP rs12248560). Genotyping was performed on the Sequenom MassARRAY iPLEX platform (Sequenom, San Diego, California, USA) and Sanger sequencing (ABI 3500 Genetic Analyzer, Applied Biosystems, Foster City, CA, USA) if the results were otherwise inconclusive. The call rate of each SNP was \>98.5%. Carriers of LOF alleles were defined as patients with at least one LOF allele (^\*^2 or ^\*^3), including the genotypes ^\*^1/^\*^2, ^\*^1/^\*^3, ^\*^2/^\*^2, ^\*^2/^\*^3, ^\*^3/^\*^3, ^\*^2/^\*^17, or ^\*^3/^\*^17. Non-carriers were defined as patients with no LOF alleles (^\*^2 or ^\*^3), including the genotypes ^\*^1/^\*^1, ^\*^1/^\*^17, or ^\*^17/^\*^17.

Statistical Analysis
--------------------

Continuous variables were presented as mean with standard deviation, or median with interquartile range, and categorical variables as percentages. Baseline characteristics were compared between ticagrelor/aspirin group and clopidogrel/aspirin group, using the Student\'s *t*-test or Wilcoxon test for continuous variables, and the χ^2^ test for categorical variables. We compared the proportion of HOPR between two treatment groups using generalized linear model, reported as a risk ratio (RR) with 95% confidence intervals (CI). At baseline, the proportion of HOPR was also compared after adjustment for age and sex. At 7 + 2 days and 90 ± 7 days, we also performed the analysis adjusted for age, sex, and HOPR status at baseline. We compared the correlation between the PL platelet analyzer and VerifyNow results by linear correlation. The differences in the rates of stroke, composite vascular events, ischemic stroke, and bleeding events during the 90 day follow-up were assessed by Cox proportional hazards regression, and were reported as hazard ratios (HR) with 95% CI. We also adjusted for age and sex. We assessed whether the treatment effect differed by testing the treatment-by-genotype interaction effect for the proportion of HOPR.

Two-sided *P* values \< 0.05 were considered statistically significant. All analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina).

Results {#s3}
=======

Study Participants and Baseline Characteristics
-----------------------------------------------

Among 675 patients enrolled in the PRINCE trial, 387 patients were included in this subgroup. Baseline characteristics of patients included and excluded in the subgroup are shown in [Table 1](#T1){ref-type="table"}. The median age of participants included in the subgroup was 61 years, and 28.4% of them were women. The index event was a minor stroke in 324 patients (83.7%) and a TIA in 63 patients (16.3%). Baseline characteristics were also compared between ticagrelor/aspirin group (197 patients) and clopidogrel/aspirin group (190 patients) and they were well balanced between two groups ([Table 2](#T2){ref-type="table"}).

###### 

Baseline characteristics of participants included and excluded in our subgroup.

  **Characteristics**                                 **Included (*N* = 387)**   **Excluded (*N* = 288)**   ***P* value**
  --------------------------------------------------- -------------------------- -------------------------- ---------------
  Age, y, median (IQR)                                61 (55--67)                61 (54--67)                0.85
  Female, *n* (%)                                     110 (28.4)                 71 (24.7)                  0.27
  BMI, kg/m^2^, median (IQR)                          24.5 (22.6--26.8)          24.9 (22.9--27.3)          0.19
  Medical history, *n* (%)                                                                                  
    Hypertension                                      238 (61.5)                 173 (60.1)                 0.71
    Dyslipidaemia                                     29 (7.5)                   12 (4.2)                   0.07
    Diabetes mellitus                                 96 (24.8)                  68 (23.6)                  0.72
    Ischemic stroke                                   73 (18.9)                  48 (16.7)                  0.46
    TIA                                               11 (2.8)                   7 (2.4)                    0.74
    Coronary artery disease                           16 (4.1)                   35 (12.2)                  \<0.0001
  Current smoker                                      171 (44.2)                 148 (51.4)                 0.08
  Drug use before randomization, *n* (%)                                                                    
    Proton-pump inhibitor                             4 (1.0)                    1 (0.4)                    0.30
    Statin                                            49 (12.7)                  17 (5.9)                   0.004
    Aspirin                                           97 (25.1)                  49 (17.0)                  0.01
    Clopidogrel                                       10 (2.6)                   5 (1.7)                    0.46
    Ticagrelor                                        0 (0.0)                    0 (0.0)                    \-
  Time from onset to randomization, h, median (IQR)   15.4 (8.5--20.8)           12.9 (7.7--20.6)           0.07
  Qualifying event, *n* (%)                                                                                 0.89
    Minor stroke                                      324 (83.7)                 240 (83.3)                 
    TIA                                               63 (16.3)                  48 (16.7)                  
  NIHSS, median (IQR); mean ± SD                      2(1--3); 1.60 ± 1.13       2(1--3); 1.63 ± 1.10       0.049
  Baseline ABCD^2^ score, median (IQR)                5 (4,5)                    5 (4,5)                    0.91
    SSS-TOAST stroke subtype, *n* (%)                                                                       0.44
    Large-artery atherosclerosis                      181 (55.9)                 123 (51.3)                 
    Cardioaortic embolism                             7 (2.2)                    6 (2.5)                    
    Small-artery occlusion                            113 (34.9)                 100 (41.7)                 
    Other causes                                      11 (3.4)                   5 (2.1)                    
    Undetermined causes                               12 (3.7)                   6 (2.5)                    

*IQR, interquartile range; SD, standard deviation; BMI, body mass index; TIA, transient ischaemic attack; ABCD^2^, age, blood pressure, clinical features, duration of TIA, and presence of diabetes score squared; SSS-TOAST, Stop Stroke Study-Trial of Org 10172 in Acute Stroke Treatment*.

###### 

Baseline characteristics of participants stratified by dual antiplatelet therapy.

  **Characteristics**                                 **Ticagrelor/aspires (*N* = 197)**   **Clopidogrel/aspirin (*N* = 190)**   ***P* value**
  --------------------------------------------------- ------------------------------------ ------------------------------------- ---------------
  **NIHSS Median (IQR)**                                                                                                         
  Age, y, median (IQR)                                62 (55--67)                          61 (55--67)                           0.55
  Female, *n* (%)                                     57 (28.9)                            53 (27.9)                             0.82
  BMI, kg/m^2^, median (IQR)                          24.3 (22.6--26.8)                    24.8 (22.6--27.0)                     0.50
  Medical history, *n* (%)                                                                                                       
    Hypertension                                      117 (59.4)                           121 (63.7)                            0.39
    Dyslipidaemia                                     15 (7.6)                             14 (7.4)                              0.93
    Diabetes mellitus                                 47 (23.9)                            49 (25.8)                             0.66
    Ischaemic stroke                                  35 (17.8)                            38 (20.0)                             0.57
    TIA                                               4 (2.0)                              7 (3.7)                               0.33
    Coronary artery disease                           10 (5.1)                             6 (3.2)                               0.34
  Current smoker, *n* (%)                             86 (43.7)                            85(44.7)                              0.91
  Drug use before randomization, *n* (%)                                                                                         
    Proton-pump inhibitor                             2 (1.0)                              2 (1.1)                               0.97
    Statin                                            29 (14.7)                            20 (10.5)                             0.21
    Aspirin                                           57 (28.9)                            40 (21.0)                             0.07
    Clopidogrel                                       3 (1.5)                              7 (3.7)                               0.18
    Ticagrelor                                        0 (0.0)                              0 (0.0)                               
  Time from onset to randomization, h, median (IQR)   15.8 (8.7--20.8)                     14.7 (8.3--20.7)                      0.46
  Qualifying event, *n* (%)                                                                                                      
    Minor stroke                                      166 (84.3)                           158 (83.2)                            0.77
    TIA                                               31 (15.7)                            32 (16.8)                             
  NIHSS, median (IQR); mean ± SD                      2(1--3); 1.62 ± 1.14                 2(1--3); 1.58 ± 1.13                  0.17
  Baseline ABCD^2^ score, median (IQR)                5(4,5)                               4.5 (4,5)                             0.94
  SSS-TOAST stroke subtype, *n* (%)                                                                                              0.23
    Large-artery atherosclerosis                      100 (60.2)                           81 (51.3)                             
    Cardioaortic embolism                             5 (3.0)                              2 (1.3)                               
    Small-artery occlusion                            53 (31.9)                            60 (38.0)                             
    Other causes                                      4 (2.4)                              7 (4.4)                               
    Undetermined causes                               4 (2.4)                              8 (5.1)                               

*IQR indicates interquartile range; SD, standard deviation; BMI, body mass index; TIA, transient ischaemic attack; ABCD^2^, age, blood pressure, clinical features, duration of TIA, and presence of diabetes score squared; SSS-TOAST, Stop Stroke Study-Trial of Org 10172 in Acute Stroke Treatment*.

Effect of Ticagrelor/Aspirin vs. Clopidogrel/Aspirin on Platelet Reactivity
---------------------------------------------------------------------------

At baseline, the proportion of HOPR between ticagrelor/aspirin group and clopidogrel/aspirin group was similar (MAR~ADP~, 72.2 vs. 76.9%, *P* = 0.29; MAR~AA~, 47.4 vs. 50.5%; *P* = 0.54). At 7 + 2 days, compared with clopidogrel/aspirin, the proportion of HOPR in ticagrelor/aspirin was significantly lower (MAR~ADP~, 19.8 vs. 33.0%; *P* = 0.005; MAR~AA~, 4.3 vs. 10.7%, *P* =0.03). At 90 ± 7 days, similar results were obtained as at 7 + 2 days (MAR~ADP~, 19.6 vs. 40.8%, *P* \< 0.001) ([Table 3](#T3){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). After adjustment for age, sex and HOPR status at baseline, similar results were obtained.

###### 

Effect of ticagrelor/aspirin vs. clopidogrel/aspirin on platelet reactivity.

  **HOPR**      **Ticagrelor/aspirin *N* (%) (*N* = 197)**   **Clopidogrel/aspirin *N* (%) (*N* = 190)**   **RR (95% CI)**   ***P* value**       **Adjusted RR (95% CI)**   ***P* value**                                       
  ------------- -------------------------------------------- --------------------------------------------- ----------------- ------------------- -------------------------- --------------------------------------------------- ---------
  Baseline      MAR~ADP~ ≥35%                                140/194 (72.2)                                143/186 (76.9)    0.94 (0.83--1.06)   0.29                       0.95(0.84--1.06)[^\#^](#TN1){ref-type="table-fn"}   0.37
                MAR~AA~ ≥35%                                 90/190 (47.4)                                 94/186 (50.5)     0.94 (0.76--1.15)   0.54                       0.93(0.76--1.15)[^\#^](#TN1){ref-type="table-fn"}   0.53
  7+2 days      MAR~ADP~ ≥35%                                37/187 (19.8)                                 59/179 (33.0)     0.60 (0.42--0.85)   0.005                      0.64(0.45--0.90)[^\*^](#TN2){ref-type="table-fn"}   0.01
                MAR~AA~ ≥35%                                 8/186 (4.3)                                   19/177 (10.7)     0.40(0.17--0.86)    0.03                       0.40(0.17--0.85)[^\*^](#TN2){ref-type="table-fn"}   0.02
  90 ± 7 days   MAR~ADP~ ≥35%                                33/168 (19.6)                                 64/157 (40.8)     0.48 (0.33--0.68)   \<0.001                    0.48(0.33--0.68)[^\*^](#TN2){ref-type="table-fn"}   \<0.001

*HOPR indicates high on-treatment platelet reactivity; MAR, maximum aggregation ratio; AA, arachidonic acid; ADP, adenosine diphosphate; RR, risk ratio; CI, confidence interval*.

*Adjusted for age and sex*.

*Adjusted for age, sex and HOPR status at baseline*.

![Proportion of HOPR stratified by dual antiplatelet therapy at baseline, 7 + 2 days and 90 ± 7 days. HOPR indicates high on-treatment platelet reactivity; AA, arachidonic acid; ADP, adenosine diphosphate.](fneur-11-00534-g0001){#F1}

At 90 ± 7 days, there were 325 patients who evaluated platelet reactivity by both the PL platelet function analyzer and VerifyNow, and we found that MAR~ADP~ moderately correlated with P2Y12 reaction unit (Pearson correlation, *r* = 0.566, *P* \< 0.001).

Effect of Ticagrelor/Aspirin vs. Clopidogrel/Aspirin on Platelet Reactivity Stratified by *CYP2C19* LOF Allele Carrier Status
-----------------------------------------------------------------------------------------------------------------------------

Among 387 patients with genetic data, 218 patients (56.3%) were *CYP2C19* LOF allele carriers and 169 (43.7%) were non-carriers. We did not identify any treatment-by-genotype interaction at the various time points ([Table 4](#T4){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}). At baseline, the proportion of HOPR was similar between two treatment groups, irrespective of the carrier status of *CYP2C19* LOF alleles. At 7 + 2 days, the proportion of HOPR on aspirin was not significantly different between two treatment groups among carriers (4.0 vs. 11.4%; *P* = 0.06) and non-carriers (4.7 vs. 9.7%; *P* = 0.22). Compared with clopidogrel/aspirin, ticagrelor/aspirin group had lower proportion of MAR~ADP~ ≥35% among carriers (18.8 vs. 33.3%, *P* = 0.02), but no significant difference was found among non-carriers (20.9 vs. 32.9%, *P* = 0.09). At 90 ± 7 days, similar results were obtained as at 7 + 2 days (carriers, 17.4 vs. 46.2%, *P* \< 0.001; non-carriers, 22.4 vs. 33.3%, *P* = 0.15). However, no significant treatment-by-genotype interactions were found (*P* for interaction = 0.12). After adjustment for age, sex, and HOPR status at baseline, similar results were obtained.

###### 

Effect of ticagrelor/aspirin vs. clopidogrel/aspirin on platelet reactivity stratified by *CYP2C19* loss-of-function allele carrier status.

  **HOPR**                                                                         **Carriers**                                                                 **Non-carriers**   ***P* for Interaction**                                                                                        
  ------------- --------------- --------------- --------------- ------------------ -------------- --------------------------------------------------- --------- ------------------ ------------------------- ------------------ ------ --------------------------------------------------- ------ ------
  Baseline      MAR~ADP~ ≥35%   79/105 (75.2)   83/109 (76.2)   0.99(0.85--1.15)   0.88           1.01(1.00--1.16)[^\#^](#TN4){ref-type="table-fn"}   0.93      61/89 (68.5)       60/77 (77.9)              0.88(0.73--1.06)   0.17   0.88(0.73--1.06)[^\#^](#TN4){ref-type="table-fn"}   0.19   0.34
                MAR~AA~ ≥35%    51/102 (50.0)   59/109 (54.1)   0.92(0.71--1.20)   0.55           0.94(0.72--1.21)[^\#^](#TN4){ref-type="table-fn"}   0.63      39/88 (44.3)       35/77 (45.5)              0.98(0.69--1.38)   0.88   0.99(0.70--1.41)[^\#^](#TN4){ref-type="table-fn"}   0.97   0.8
  7 + 2 days    MAR~ADP~ ≥35%   19/101 (18.8)   35/106 (33.0)   0.57(0.34--0.91)   0.02           0.61(0.37--0.96)[\*](#TN3){ref-type="table-fn"}     0.04      18/86 (20.9)       24/73 (32.9)              0.64(0.37--1.07)   0.09   0.73(0.42--1.23)[\*](#TN3){ref-type="table-fn"}     0.24   0.76
                MAR~AA~ ≥35%    4/100 (4.0)     12/105 (11.4)   0.35(0.10--0.97)   0.06           0.38(0.11--1.06)[\*](#TN3){ref-type="table-fn"}     0.09      4/86 (4.7)         7/72 (9.7)                0.48(0.13--1.52)   0.22   0.48(0.13--1.51)[\*](#TN3){ref-type="table-fn"}     0.22   0.7
  90 ± 7 days   MAR~ADP~ ≥35%   16/92 (17.4)    42/91 (46.2)    0.38(0.22--0.60)   \<0.001        0.38(0.22--0.61)[\*](#TN3){ref-type="table-fn"}     \<0.001   17/76 (22.4)       22/66 (33.3)              0.67(0.38--1.15)   0.15   0.70(0.39--1.22)[\*](#TN3){ref-type="table-fn"}     0.22   0.12

*HOPR, high on-treatment platelet reactivity; MAR, maximum aggregation ratio; AA, arachidonic acid; ADP, adenosine diphosphate*.

*Carriers, defined as patients who carried at least one CYP2C19 loss-of-function allele (\*2 or \*3)*.

*Non-carriers, defined as patients who did not carry either of CYP2C19 loss-of-function alleles (\*2 or \*3)*.

*RR, risk ratio; CI, confidence interval*.

*Adjusted for age and sex*.

*Adjusted for age, sex and HOPR status at baseline*.

![Proportion of HOPR stratified by dual antiplatelet therapy and *CYP2C19* loss-of-function allele carrier status at baseline, 7 + 2 days and 90 ± 7 days. HOPR indicates high on-treatment platelet reactivity; AA, arachidonic acid; ADP, adenosine diphosphate.](fneur-11-00534-g0002){#F2}

Effect of Ticagrelor/Aspirin vs. Clopidogrel/Aspirin on Clinical Outcomes
-------------------------------------------------------------------------

At 90 ± 7 days, a trend toward a lower risk of new stroke in ticagrelor/aspirin compared to clopidogrel/aspirin was observed (4.6 vs. 9.5%, HR 0.47, 95% CI 0.21-1.05, *P* = 0.06). Compared with clopidogrel/aspirin, ticagrelor/aspirin reduced the occurrence of composite events (5.1 vs. 10.5%, HR 0.47, 95% CI 0.22-1.00, *P* = 0.050) and ischemic stroke (3.6 vs. 9.0%, HR 0.39, 95% CI 0.16-0.93, *P* = 0.03). No significant differences in the risk of major bleeding or any bleeding were observed between two groups ([Table 5](#T5){ref-type="table"}). After adjustment for age and sex, similar results were obtained.

###### 

Effect of ticagrelor/aspirin vs. clopidogrel/aspirin on clinical outcomes within 90 days.

  **Outcome**                 **Ticagrelor/Aspirin N (%) (*N* = 197)**   **Clopidogrel/Aspirin *N* (%) (*N* = 190)**   **HR (95%CI)**     ***P* value**   **Adjusted HR (95%CI)[^\#^](#TN5){ref-type="table-fn"}**   ***P* value**
  --------------------------- ------------------------------------------ --------------------------------------------- ------------------ --------------- ---------------------------------------------------------- ---------------
  **Efficacy outcome**                                                                                                                                                                                               
  Stroke                      9(4.6)                                     18(9.5)                                       0.47(0.21--1.05)   0.06            0.47(0.21--1.04)                                           0.06
  Composite vascular events   10(5.1)                                    20(10.5)                                      0.47(0.22--1.00)   0.050           0.47(0.22--1.00)                                           0.049
  Ischemic stroke             7(3.6)                                     17(9.0)                                       0.39(0.16--0.93)   0.03            0.38(0.16--0.92)                                           0.03
  **Safety outcome**                                                                                                                                                                                                 
  Major bleeding              2(1.0)                                     2(1.1)                                        0.97(0.14--6.87)   0.97            1.02(0.14--7.29)                                           0.98
  Any Bleeding                39(19.8)                                   25(13.2)                                      1.57(0.95--2.59)   0.08            1.57(0.95--2.60)                                           0.08

*CI indicates confidence interval*.

*Adjusted for age and sex*.

Discussion {#s4}
==========

The pre-specified subgroup analysis of the PRINCE trial confirmed the finding of the main analysis with the PL platelet function analyzer: ticagrelor is superior to clopidogrel in inhibiting platelet reactivity among patients with acute minor stroke or TIA. Our study also afforded more evidence for the application of the PL platelet function analyzer in assessing the efficacy of antiplatelet therapies in these patients.

The PL subgroup analysis has made a consistent conclusion with the main analysis of the PRINCE trial in which 675 patients were enrolled and platelet reactivity was assessed by VerifyNow P2Y12 assay ([@B16]). The VerifyNow P2Y12 assay is the most widely described method in clinical trials to assess platelet reactivity to clopidogrel or ticagrelor ([@B17], [@B23], [@B24]). Our study also showed that PL platelet function analyzer results moderately correlated with VerifyNow, suggesting that the new method is reliable in assessing the treatment effects of antiplatelet drugs. Among patients undergoing percutaneous coronary intervention, HOPR measured by the PL platelet function analyzer was associated with incremental stent thrombosis ([@B25]). The cut-off values (MAR~ADP~ ≥ 35%, MAR~AA~ ≥ 35%) had been previously confirmed to predict a higher risk of ischemic stroke or TIA ([@B21]). In addition, considering that the method is cheap, quick and easy to monitor platelet function, PL platelet function analyzer might be widely used in clinical practice.

The conversion of clopidogrel to its active metabolite is regulated by the cytochrome P450 system, especially *CYP2C19*. The findings from a meta-analysis showed that carriers of *CYP2C19* LOF alleles had attenuated responses to clopidogrel in patients with acute minor stroke or TIA ([@B8]). Ticagrelor does not require metabolic activation after ingestion, and inhibits platelet reactivity directly. Our study found that ticagrelor had a lower platelet reactivity than clopidogrel among carriers, but not among non-carriers. We speculated that the superiority of ticagrelor over clopidogrel in inhibiting platelet reactivity among carriers of *CYP2C19* LOF alleles was mainly associated with reduced clopidogrel metabolism. Carriers of *CYP2C19* LOF alleles might achieve more benefit with ticagrelor than clopidogrel. It might be necessary to conduct genetic testing before an individualized antiplatelet therapy was given ([@B12]). However, our results showed that there was no significant interaction between treatment groups and the carrier status of *CYP2C19* LOF alleles, and this may be related to limited sample size. Large randomized controlled trials are needed to evaluate this.

Our study also found that ticagrelor plus aspirin reduced the proportion of HOPR on aspirin compared with clopidogrel plus aspirin at 7 + 2 days. The platelet aggregation induced by AA depends on the activity of the cyclo-oxygenase-1 (COX-1) enzyme, and aspirin irreversibly inhibits this enzyme. Both ticagrelor and clopidogrel inhibit the P2Y12 receptor, which is the downstream of the COX-1 pathway. Our results indicated that ticagrelor might be superior to clopidogrel not only in inhibiting the platelet aggregation induced by ADP, but also in inhibiting the platelet aggregation induced by AA.

There were several advantages in our study. First, the data was from a randomized controlled trial, thus diminishing the effect of potential confounding factors as much as possible. Second, both platelet reactivity and clinical outcomes were analyzed to investigate the impact of ticagrelor vs. clopidogrel on platelet function among patients with minor stroke or TIA. There were several limitations. First, some factors might affect the interpretation of platelet reactivity assessed by PL platelet function analyzer, such as the coagulation function, mean platelet volume, and the number of platelets before the measurements. Second, about 15% of the patients were lost to follow-up for the evaluation of platelet function at 90 days. However, similar results were observed after assuming that all the missing data were HOPR, or not. Third, baseline characteristics of patients included and excluded in this subgroup were not totally balanced, including the proportions of patients with coronary artery disease and pre-randomization statin and aspirin use, and NIHSS score. Therefore, the generalization of our results is limited and more randomized trails are needed to confirm them.

In summary, ticagrelor is superior to clopidogrel in inhibiting platelet reactivity measured by the PL platelet function analyzer among patients with acute minor stroke or TIA. Our study confirmed the finding of the main analysis of PRINCE trial in a different assay. Large randomized controlled trials are needed to evaluate our findings.
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